# Clinical Translational & Implementation Core

> **NIH NIH P30** · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2021 · $757,368

## Abstract

Abstract
The AIDS research community and public health systems locally, nationally and globally now
can envision the end of the AIDS epidemic. Our Einstein/Rockefeller/CUNY (ERC)-CFAR has
formed new collaborations both within and beyond our partner institutions to catalyze and
support research that best serves the public's health: to eradicate HIV infection, prevent new
HIV infections, and improve the health of those living with HIV (PLWH). The overarching goal of
the ERC-CFAR and this Core for Clinical, Translational and Implementation Science (CTISC) is
to meet this vision by creating a broad robust resource available to researchers both within our
walls as well as nationally and globally. Our synergistic partnership provides all the services
needed to support clinical, translational and implementation projects. By leveraging the
resources of the Einstein CTSA-funded Institute for Clinical and Translational Research, the
CTISC provides access to three robust clinical databases. The Clinical Cohort, from the
Montefiore/Einstein clinical services, has over 16,000 PLWH and 285,000 HIV-negative patients.
This dynamic, comprehensive, longitudinal database accesses Montefiore's extensive clinical
infrastructure to facilitate enrollment of well-characterized patients (including HIV-negative
controls) into new research protocols. We have established collaborations to use the clinical
population at Einstein to enable research at Rockefeller, which lacks access to defined cohorts
of PLWH, recruiting new participants for Rockefeller's cutting edge research in HIV eradication.
City University of New York (CUNY) is a leader in implementation science assessing the factors
that influence our ability to impact favorably on the public's health with interventions of proven
efficacy. The CTISC is integrated into the Scientific Working Groups, the drivers of the ERC-
CFAR's scientific direction, to provide optimal support to the emerging research activities, and
foster cross-fertilization among cores and SWGs. With institutional funding we have fostered
multiple new implementation science investigations across institutions, increased enrollment in
critical clinical trials of broadly neutralizing antibodies, and supported epidemiologic and clinical
research that can contribute to ending the epidemic.

## Key facts

- **NIH application ID:** 10147763
- **Project number:** 5P30AI124414-06
- **Recipient organization:** ALBERT EINSTEIN COLLEGE OF MEDICINE
- **Principal Investigator:** Kathryn M. Anastos
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $757,368
- **Award type:** 5
- **Project period:** 2017-05-01 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10147763

## Citation

> US National Institutes of Health, RePORTER application 10147763, Clinical Translational & Implementation Core (5P30AI124414-06). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10147763. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*